Cochrane · systematic review · CD010017
Anti‐TNF agents for paediatric psoriasis
Sanclemente, G, Murphy, R, Contreras, J, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 20%High 4 · 80%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Etanercept compared to placebo for paediatric psoriasis
Population: people with paediatric psoriasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PASI 75 Participants achieving a 75% improvement in the Psoriasis Area and Severity Index Etanercept vs placebo | RR 4.95 [2.83, 8.65] | 1 study · 211 participants | High |
PASI 50 Participants achieving a 50% improvement in the Psoriasis Area and Severity Index Etanercept vs placebo | RR 3.26 [2.26, 4.71] | 1 study · 211 participants | High |
PASI 90 Participants achieving a 90% improvement in the Psoriasis Area and Severity Index Etanercept vs placebo | RR 4.1 [1.88, 8.95] | 1 study · 211 participants | High |
PGA Participants achieving a PGA of 'clear' or 'almost clear' Etanercept vs placebo | RR 3.96 [2.36, 6.66] | 1 study · 211 participants | High |
CDLQI Scores range from 0 to 30. Lower scores indicate better health‐related quality of life. Calculations are based on the change from baseline to week 12 in both groups Etanercept vs placebo | no estimate extracted | 1 study · 211 participants | Moderate Downgraded: risk of bias |